ATRC

NEUTRALAnalyst

AtriCure, Inc.

2026-09-14

Price

$55.79

+2.29%

This is the 2026-09-14 snapshot — the signals and analysis for ATRC as of this single trading day.

View full ATRC research hub →

Score3.8Watchlist

Signals5/8 DNA0/13 Act · 3/4 Risk

SentimentNEUTRALScore: 8

Volume1.3xvs 20d avg

Analysis

AtriCure (ATRC) is breaking out to fresh 52-week highs because of a wave of bullish analyst price target hikes and strong clinical tailwinds. Recent price target increases from Piper Sandler and Needham are driving heavy institutional accumulation, directly reflected in the stock's SURGE and PERFECT_STACK technical signals on 1.3x average volume. Operating in a RISK_ON macro regime characterized by abundant liquidity and exceptionally tight credit spreads, this setup offers high conviction that the market is rewarding AtriCure's fundamental momentum rather than just drifting with the tape.

Fired Signals

SURGEALPHA MALEGOLDEN CROSSMARKET LEADERPERFECT STACKWEAK FINISHEXTENSIONDISTRIBUTION

Key Takeaways

Actionable Thesis: High-Conviction Price Discovery is underway as institutions aggressively buy into recent analyst upgrades and favorable clinical metrics, fueling strong relative strength (+28.2% vs SPY).
Key Risk: Insider profit-taking at 52-week highs, evidenced by recent director sales, could create overhead supply and momentarily stall the breakout.
What to Watch: The $44.77 structural support level serves as the ultimate line-in-the-sand to maintain the PERFECT_STACK and MARKET_LEADER technical thesis.

← Back to 2026-09-14 View Full ATRC History →Yahoo Finance &nearr;